We still have EyesOn Clinical Asset updates. This week we cover GSK's FDA approval for Jideytro, Royalty's ATTR deal, plus the Sanofi and Roche portfolio adjustments that include discontinuation of some assets.

We've been keeping EyesOn Strategic moves in the BioPharma space. Today we look at BioNTech's new CEO, Pfizer's continuing restructuring moves to remain competitive, and the reactions to a potential BMS + AZN merger.

We've had EyesOn recent clinical trial updates. Otsuka Pharma received approval for their ADHD therapy, Simtriyo, potentially a game changer for patients aged 6 and older. Meanwhile, Sanofi has stopped development of SAR445399, in bronchiectasis patients without cystic fibrosis as part of ther Portfolio re-alignment efforts.

This week we had EyesOn Merck KGaA and Sanofi and their corporate activities. Read about the antitrust proceedings against Sanofi and their Flu vaccine, and how the new CEO of Merck is changing their strategic direction with M&A.

This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

This week we're sharing a couple of articles focused on competitive advantage in US BioPharma. Take a look at how the Oral GLP-1 market is shaping up, and the new US Initiative Operation TrialBlazer is trying to boost US Early-Stage Clinical Development Capabilities.

This week we've had EyesOn all the recent Business Development activities in the BioPharma world. We're sharing a few that caught our eye. Check out AbbVie's acquisition of Apogee to strengthen out their I&I portfolio, Sangamo's asset sale, and Pfizer's recent clinical results from one of their Seagen candidates.

Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

EyesOn Strategic Agility in Action: How Biopharma Companies Are Managing Clinical, Commercial, and Operational Levers to Sustain Growth

Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.